Clinical and pathogenetic justification of the use of azathioprine in the treatment of progressive non-segmental vitiligo

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Vitiligo refers to acquired hypomelanosis, characterized by the appearance of depigmented spots on the skin. The search for new vitiligo treatment approaches, which would simultaneously have a pathogenetic focus on the therapy of this disease and at the same time have a safe spectrum of side effects, is relevant today.

AIM: to evaluate the clinical and laboratory efficacy of azathioprine in progressive non-segmental vitiligo compared with NB-UVB monotherapy.

MATERIALS AND METHODS: 60 patients with progressive non-segmental vitiligo were divided into 2 equal groups: group 1 received azathioprine in combination with NB-UVB, group 2 received NB-UVB monotherapy. The follow-up period was 6 months. The effectiveness of therapy was evaluated based on the dynamics of the Vitiligo Area Scoring Index (VASI), dermatological quality of life index (DLQI), as well as the titers of proinflammatory cytokines IL-1ß, IL-2, IL-6, IL-8, IFN-γ, TNF-α and S100 protein in serum blood.

RESULTS: In the azathioprine + NB-UVB group, compared with the control group, a statistically significant prevalence of VASI and DLQI indices reduction was observed. (Me -61.70%, Q1–Q3: -75.14…-47.08%, p <0.001; Me -55.83%, Q1–Q3: -67.80…-40.29%, p <0.001). The dependence of the quality of life of patients on the prevalence of the skin process was noted (p <0.001). There was a statistically significant relationship between the activity of the skin process and the S100 protein in the blood serum of patients with vitiligo. (p <0.05) In addition, the analysis of the dynamics of immunological parameters of the main group compared with the control group showed a more significant decrease in the level of cytokines, as well as S100 protein in blood serum (p <0.001).

CONCLUSION: The combination of azathioprine and NB-UVB is effective and safe, helps to stabilize the skin process and stimulate the repigmentation of foci, significantly improving the quality of life of patients, contributes to the normalization of immunological parameters, leading to an earlier stop of the progression of the skin process.

全文:

受限制的访问

作者简介

Kseniia Vovdenko

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

编辑信件的主要联系方式.
Email: vovdenkoksenia@ya.ru
ORCID iD: 0000-0003-1415-3940
SPIN 代码: 8315-2175

Graduate Student

俄罗斯联邦, Moscow

Olga Olisova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN 代码: 2500-7989

MD, Dr. Sci. (Med.), Professor, Corresponding member of the Russian Academy of Sciences

俄罗斯联邦, Moscow

Konstantin Smirnov

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: puva3@mail.ru
ORCID iD: 0000-0001-7660-7958
SPIN 代码: 2054-1086

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Daria Svistunova

Saratov State Medical University named after V.I. Razumovsky

Email: svistunova@mail.ru
ORCID iD: 0009-0004-4268-8824

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saratov

Konstantin Lomonosov

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN 代码: 4784-9730

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

参考

  1. Bergqvist C, Ezzedine K. Vitiligo: A review. Dermatology. 2020;236(6):571–592. doi: 10.1159/000506103
  2. Salzes C, Abadie S, Seneschal J, et al. The vitiligo impact patient scale (VIPs): Development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136(1):52–58. doi: 10.1038/JID.2015.398
  3. Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: Patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61(3):411–420. doi: 10.1016/J.JAAD.2009.03.022
  4. Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35(2):117–128. doi: 10.1016/J.DET.2016.11.002
  5. Badran AY, Gomaa AS, El-Mahdy RI, et al. Serum level of S100B in vitiligo patients: Is it a marker of disease activity? Australas J Dermatol. 2021;62(1):e67–e72. doi: 10.1111/ajd.13462
  6. Speeckaert R, Voet S, Hoste E, van Geel N. S100B is a potential disease activity marker in nonsegmental vitiligo. J Invest Dermatol. 2017;137(7):1445–1453. doi: 10.1016/j.jid.2017.01.033
  7. Shabaka FH, Rashed LA, Said M, Ibrahim L. Sensitivity of serum S100B protein as a disease activity marker in Egyptian patients with vitiligo (case-control study). Arch Physiol Biochem. 2022;128(4):930–937. doi: 10.1080/13813455.2020.1739717
  8. Rashighi M, Harris JE. Vitiligo pathogenesis and emerging treatments. Dermatol Clin. 2017;35(2):257–265. doi: 10.1016/J.DET.2016.11.014
  9. Katz EL, Harris JE. Translational research in vitiligo. Front Immunol. 2021;(12):624517. doi: 10.3389/FIMMU.2021.624517/BIBTEX
  10. Marchioro HZ, de Castro CC, Fava VM, et al. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478. doi: 10.1016/J.ABD.2021.09.008
  11. Luiten RM, van Den Boorn JG, Konijnenberg D, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129(9):2220–2232. doi: 10.1038/JID.2009.32
  12. Custurone P, Di Bartolomeo L, Irrera N, et al. Role of cytokines in vitiligo: Pathogenesis and possible targets for old and new treatments. Int J Mol Sci. 2021;22(21):11429. doi: 10.3390/IJMS222111429
  13. Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407. doi: 10.1111/PCMR.12219
  14. Jacquemin C, Rambert J, Guillet S, et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: Relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol. 2017;177(5):1367–1375. doi: 10.1111/BJD.15550
  15. Kasumagic-Halilovic E, Ovcina-Kurtovic N, Soskic S, et al. Serum levels of interleukin-2 and interleukin-2 soluble receptor in patients with vitiligo. Br J Med Med Res. 2016;13(10):1–7. doi: 10.9734/BJMMR/2016/23959
  16. Shi YL, Li K, Hamzavi I, et al. Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American. J Dermatol Sci. 2013;71(3):212–214. doi: 10.1016/J.JDERMSCI.2013.04.032
  17. Singh S, Singh U, Pandey SS. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol. 2012;57(1):12–14. doi: 10.4103/0019-5154.92668
  18. Miniati A, Weng Z, Zhang B, et al. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol. 2014;39(1):54–57. doi: 10.1111/CED.12164
  19. Babeshko A, Lomonosov KM, Gilyadova NI. The role of cytokines in the pathogenesis of vitiligo. Russ Skin Venereal Dis. 2012;15(3):37–41. (In Russ). doi: 10.17816/dv36685.
  20. Schallreuter KU, Krüger C, Würfel BA, et al. From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol. 2008;47(7):743–753. doi: 10.1111/J.1365-4632.2008.03660.X
  21. Cheong KA, Noh M, Kim CH, Lee AY. S100B as a potential biomarker for the detection of cytotoxicity of melanocytes. Exp Dermatol. 2014;23(3):165–171. doi: 10.1111/exd.12332
  22. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60(6):614–632. doi: 10.1002/jemt.10303
  23. Federal clinical guidelines for the management of patients with vitiligo. Moscow: Russian Society of Dermatovenerologists and Cosmetologists; 2020. 16 р. (In Russ).
  24. Karagaiah P, Valle Y, Sigova J, et al. Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs. 2020;25(1):7–24. doi: 10.1080/14728214.2020.1712358
  25. Davletshina AY, Lomonosov KM. Pathogenetic justification of the use of simvastatin in the complex therapy of vitiligo. Russ J Skin Venereal Dis. 2021;24(3):227–242. (In Russ). doi: 10.17816/dv62227
  26. Davletova AR, Lomonosov KM. Clinical and pathogenetic justification of the use of methotrexate in the treatment of progressive non-segmental vitiligo. Russ J Skin Venereal Dis. 2022;25(1):17–27. (In Russ). doi: 10.17816/dv105122
  27. Van Scoik KG, Johnson CA, Porter WR. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev. 1985;16(1-2):157–174. doi: 10.3109/03602538508991433
  28. Okovity SV. Clinical pharmacology of immunosuppressants. Rev Clin Pharmacol Drug Ther. 2003;2(2):2–34. (In Russ).
  29. Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2009;17(3):151–153. doi: 10.1080/09546630600791442
  30. Madarkar M, Ankad B, Manjula R. Comparative study of safety and efficacy of oral betamethasone pulse therapy and azathioprine in vitiligo. Clin Dermatology Rev. 2019;3(2):121. doi: 10.4103/CDR.CDR_13_18

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. A graph of the regression function characterizing the dependence of DLQI on VASI after treatment. Note: ДИКЖ ― Dermatology life quality index (DLQI); VASI ― Vitiligo area scoring index.

下载 (311KB)
索引源数据
3. Fig. 2. The results of azathioprine therapy in combination with NB-UVB: а ― before treatment; b ― after 6 months of therapy.

下载 (293KB)
索引源数据
4. Fig. 3. The results of azathioprine therapy in combination with NB-UVB: а ― before treatment; b ― after 6 months of therapy.

下载 (447KB)
索引源数据

版权所有 © Vovdenko K.A., Olisova O.Y., Smirnov K.V., Svistunova D.A., Lomonosov K.M., 2023

许可 URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


##common.cookie##